CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 57 filers reported holding CITIUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,026 | -58.3% | 76,016 | -26.9% | 0.00% | – |
| Q2 2023 | $124,825 | -21.8% | 104,021 | -23.8% | 0.00% | – |
| Q1 2023 | $159,692 | +81.5% | 136,489 | +22.6% | 0.00% | – |
| Q4 2022 | $87,986 | -50.8% | 111,374 | -25.0% | 0.00% | – |
| Q3 2022 | $179,000 | -6.3% | 148,510 | -28.5% | 0.00% | – |
| Q2 2022 | $191,000 | +130.1% | 207,751 | +349.6% | 0.00% | – |
| Q1 2022 | $83,000 | +36.1% | 46,212 | +14.2% | 0.00% | – |
| Q4 2021 | $61,000 | +144.0% | 40,474 | +226.5% | 0.00% | – |
| Q3 2021 | $25,000 | -16.7% | 12,398 | +41.8% | 0.00% | – |
| Q2 2021 | $30,000 | -57.7% | 8,745 | -78.1% | 0.00% | – |
| Q1 2021 | $71,000 | +144.8% | 40,000 | +90.5% | 0.00% | – |
| Q1 2019 | $29,000 | – | 21,000 | +52400.0% | 0.00% | – |
| Q3 2018 | $0 | – | 40 | +135.3% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 17 | -91.9% | 0.00% | – |
| Q3 2017 | $1,000 | – | 210 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Inspire Advisors, LLC | 196,867 | $181,000 | 0.05% |
| Wealth Advisory Solutions, LLC | 156,850 | $144,000 | 0.04% |
| Horst & Graben Wealth Management LLC | 75,722 | $70,000 | 0.02% |
| Ergoteles LLC | 451,890 | $416,000 | 0.01% |
| Miller Investment Management, LP | 50,000 | $46,000 | 0.01% |
| Virtu Financial LLC | 81,410 | $75,000 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,342 | $16,000 | 0.00% |
| Kestra Advisory Services, LLC | 71,102 | $65,000 | 0.00% |
| Csenge Advisory Group | 15,000 | $14,000 | 0.00% |
| Qube Research & Technologies Ltd | 121,281 | $112,000 | 0.00% |